In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

All the symptoms and pathology of malaria are caused by the intraerythrocytic stages of the
Plasmodium parasite life cycle. Because Plasmodium parasites cannot replicate outside a …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

Antigenic diversity has posed a critical barrier to vaccine development against the
pathogenic blood-stage infection of the human malaria parasite Plasmodium falciparum. To …

The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the leading
target for next-generation vaccines against the disease-causing blood-stage of malaria …

Erythrocyte invasion by Plasmodium falciparum merozoites is a highly intricate process in
which Plasmodium falciparum reticulocyte binding-like homologous protein 5 (PfRH5) is an …

Invasion of host erythrocytes is essential to the life cycle of Plasmodium parasites and
development of the pathology of malaria. The stages of erythrocyte invasion, including initial …

The development of a highly effective vaccine remains a key strategic goal to aid the control
and eventual eradication of Plasmodium falciparum malaria. In recent years, the reticulocyte …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Despite ongoing efforts, a highly effective vaccine against Plasmodium falciparum remains
elusive. Vaccines targeting the pre-erythrocytic stages of the P. falciparum life cycle are the …